Exposure to ultrafine carbon particles at levels below detectable pulmonary inflammation affects cardiovascular performance in spontaneously hypertensive rats
© Upadhyay et al; licensee BioMed Central Ltd. 2008
Received: 10 September 2008
Accepted: 04 December 2008
Published: 04 December 2008
Exposure to particulate matter is a risk factor for cardiopulmonary disease but the underlying molecular mechanisms remain poorly understood. In the present study we sought to investigate the cardiopulmonary responses on spontaneously hypertensive rats (SHRs) following inhalation of UfCPs (24 h, 172 μg·m-3), to assess whether compromised animals (SHR) exhibit a different response pattern compared to the previously studied healthy rats (WKY).
Cardiophysiological response in SHRs was analyzed using radiotelemetry. Blood pressure (BP) and its biomarkers plasma renin-angiotensin system were also assessed. Lung and cardiac mRNA expressions for markers of oxidative stress (hemeoxygenase-1), blood coagulation (tissue factor, plasminogen activator inhibitor-1), and endothelial function (endothelin-1, and endothelin receptors A and B) were analyzed following UfCPs exposure in SHRs. UfCPs-mediated inflammatory responses were assessed from broncho-alveolar-lavage fluid (BALF).
Increased BP and heart rate (HR) by about 5% with a lag of 1–3 days were detected in UfCPs exposed SHRs. Inflammatory markers of BALF, lung (pulmonary) and blood (systemic) were not affected. However, mRNA expression of hemeoxygenase-1, endothelin-1, endothelin receptors A and B, tissue factor, and plasminogen activator inhibitor showed a significant induction (~2.5-fold; p < 0.05) with endothelin 1 being the maximally induced factor (6-fold; p < 0.05) on the third recovery day in the lungs of UfCPs exposed SHRs; while all of these factors – except hemeoxygenase-1 – were not affected in cardiac tissues. Strikingly, the UfCPs-mediated altered BP is paralleled by the induction of renin-angiotensin system in plasma.
Our finding shows that UfCPs exposure at levels which does not induce detectable pulmonary neutrophilic inflammation, triggers distinct effects in the lung and also at the systemic level in compromised SHRs. These effects are characterized by increased activity of plasma renin-angiotensin system and circulating white blood cells together with moderate increases in the BP, HR and decreases in heart rate variability. This systemic effect is associated with pulmonary, but not cardiac, mRNA induction of biomarkers reflective of oxidative stress; activation of vasoconstriction, stimulation of blood coagulation factors, and inhibition of fibrinolysis. Thus, UfCPs may cause cardiovascular and pulmonary impairment, in the absence of detectable pulmonary inflammation, in individuals suffering from preexisting cardiovascular diseases.
Epidemiological studies have identified exposure to elevated concentrations of ultrafine particles (UFPs; < 100 nm) in the air as a risk factor for the exacerbation of ischemic heart disease and congestive heart failure with specific physiological end points like arrhythmias, reduced heart-rate variability (HRV), elevated heart rate (HR) and atherosclerosis in adults [1–4]. However, the underlying pathophysiologcal mechanisms of airborne UFPs mediated cardiopulmonary mortality and morbidity are complex and remain to a large extent unexplored [5, 6]. Although humans have been exposed to airborne UFPs throughout evolution, such exposure has increased dramatically over the last decades mainly due to increased emissions of combustion derived UFPs, e.g. from motor vehicles . Thus, specific information about the molecular and pathophysiologcal mechanism involved in the cardiovascular impairments following exposure to UFPs is urgently required.
Dysfunction of the autonomic nervous system, i.e., an altered autonomic balance is amongst the recently discussed plausible biological mechanisms linking UFPs exposure with increased cardiovascular risk [2, 8–10]. Exposure to airborne UFPs may cause a low-grade pulmonary inflammation by inducing the generation of reactive oxygen species and pro-inflammatory cytokines like TNF-α, IL-1, IL-6 . This could be associated with increased plasma viscosity ; blood coagulability , vascular and endothelial dysfunction [14, 15]. Furthermore, there are evidences that UFPs deposited in the lung gain access to the systemic circulation and translocate into extra-pulmonary organs, such as liver, heart, and brain [16, 17]. This may disturb the blood coagulation balance by activating circulating platelets [18, 19] but may also induce dysfunction in secondary target organs [20, 21].
Previous studies from our laboratory  focussed on cardiovascular responses in young and healthy WKY (normotensive) rats following inhalation exposure to ultrafine carbon particles (UfCPs). The observed transient increase in HR associated with a decrease in HRV during exposure suggested an altered sympatho-vagal balance due to neural pathway activation in response to UfCPs inhalation . Epidemiological studies have provided evidence that individuals with cardiovascular disease are at higher risk when exposed to elevated levels of ambient particles. Therefore, in this study we sought to investigate cardiopulmonary responses to UfCPs in spontaneously hypertensive rats (SHRs; 6 months), a well established animal model of human cardiovascular disease and assessed whether compromised animals (SHR) exhibit a different response pattern compared to what has been previously observed in healthy Wistar Kyoto (WKY) rats .
Compared to transient increases of HR during UfCPs exposure followed by a moderate pulmonary neutrophilic inflammation in WKY rats , SHRs demonstrated no sign of pulmonary neutrophilic inflammation or inflammatory mediator release, but obvious increases of HR and blood pressure (BP) for over a longer period of time after 24 h UfCPs inhalation (a lag of 1–3 days). Our mRNA expression and other biomarker data show that UfCPs exposure triggers distinct effects in the pulmonary tissue and also at the systemic level which can contribute to the observed cardiovascular impairments. Increases in BP along with induction of plasma renin-angiotensin system and increased expression for biomarkers of pulmonary oxidative stress; endothelial activation, and blood coagulation following exposure to UfCPs in cardiovascular compromised SHRs support the observed epidemiological findings of increased cardiovascular mortality as a result of exposure to peak ambient ultrafine particles concentrations.
Cardiophysiological response assessed by radio telemetry
Figures 2a and 2b display mean values (± SE) for mean arterial blood pressure (mBP) and HR during dark periods of baseline, exposure and recovery. Following 24 h exposure to UfCPs mBP increased by about 6 mmHg, (control/exposure: 176 ± 2.0/182 ± 2.1 mmHg; about 4%, p < 0.05) on the first and second day of recovery in exposed SHRs, and returned to baseline levels on the fourth day of recovery. This is due to the concurrent increase in systolic (control/exposure: 194 ± 2.8/204 ± 2.5 mmHg) and diastolic BP (control/exposure: 158 ± 1.5/160 ± 1.8 mmHg) with the systolic being more pronounced. In comparison to the BP response, HR responded with a lag of one day, it increased on the second and third day of recovery by about 17 bpm, (control/exposure: 328 ± 3.5/345 ± 3.5 bpm; about 5%, p < 0.05) and reached baseline values on the fourth day of recovery. UfCP exposure did not affect body temperature or activity levels of the animals. Both remained unaffected in UfCPs exposed SHRs compared to their control (Figures 2c and 2d).
Pulmonary inflammatory response
BALF and lung
BALF derived parameters obtained on first and third recovery day showed no signs of UfCPs exposure related inflammatory response in the lungs. Cell numbers and cell differentials of the BALF (Total cell: control/exposed: 3.7 ± 0.2/4.7 ± 0.2; PMN: control/exposed: 0.3 ± 0.1/0.4 ± 0.1) were not affected in exposed SHRs. BALF protein (control/exposed: 137 ± 32/135 ± 34 μg/ml), albumin concentrations (control/exposed: 18 ± 5/15 ± 5 μg/ml), and γ-Glutamyltransferase (GGT; control/exposed: 4.9 ± 0.4/4.8 ± 0.5 U/l) activity were used as markers of pulmonary capillary leakage or pulmonary cell membrane integrity; whereas N-acetyl glucosaminidase (NAG; control/exposed: 5.3 ± 0.5/5.8 ± 0.7 U/l) activity in BALF indicate macrophage phagocytic ability. None of these markers from BALF showed any significant changes in exposed SHRs. The pulmonary cytokine IL-6 in BALF samples of exposed SHRs showed a slight, 10% increase (control/exposed: 83 ± 6.2/92 ± 4.1 pg/ml), but differences were not statistically significant. Furthermore, transcript profiling markers associated with inflammation (MIP-2, TNF-α), were assessed from the lung tissues on first and third recovery day. Corresponding to the findings in BALF, expression of MIP-2 and TNF-α were not significantly altered on both days (data not shown).
Pulmonary histopathology analysis also revealed no signs of pulmonary inflammation in the UfCPs exposed animal group (data not shown).
UfCPs-mediated direct effect on pulmonary and cardiac tissue
Pulmonary mRNA expression
Cardiac mRNA expression
To assess whether pulmonary and cardiac tissue exhibited a comparable response, HO-1, ET-1, ETA, ETB, PAI-1 and TF were also measured in the cardiac tissues on the first and third day of recovery. Compared to the lung only slight but non significant exposure related increases were detected in the cardiac tissues. Strikingly, HO-1 was repressed by over 2-fold in the heart in contrast to its more than 2-fold induction in the lung on the third day of recovery (Figures 4 a–f, right column).
Histological analysis revealed fibrotic foci (typical for SHRs), but no signs of inflammation or cardiomyopathy following exposure to UfCPs (data not shown).
Acute phase proteins
To assess whether UfCPs exposure induces an inflammatory response at the systemic level the acute phase reactants, C-reactive protein (CRP; control/exposed: 92 ± 3.8/94 ± 3 μg/ml)), haptoglobin (HP; control/exposed: 300 ± 17/309 ± 20 mg/dl)) and fibrinogen (control/exposed: 190 ± 11.4/198 ± 5.2 mg/dl) were determined from serum and plasma. None of these markers revealed any significant changes in exposed SHRs compared to the control groups.
Haematological analysis of filtred air (control;n = 8) and ultrafine carbon particles (UfCPs;n = 8) exposed SHRs on first and third recovery day.
First recovery day
Third recovery day
RBC (×103 cells/μl)
7.92 ± 0.36
9.6 ± 0.3
8.29 ± 0.22
9.41 ± 0.11
WBC (×103 cells/μl)
6.19 ± 0.4
5.79 ± 0.5
8.7 ± 0.9
6.6 ± 0.7
PLT (×103 cells/μl)
436 ± 30.2
443.8 ± 48.4
611 ± 22
582 ± 24
44.8 ± 0.8
43.8 ± 2.1
46 ± 1.2
44 ± 0.4
0.51 ± 0.04
0.39 ± 0.05
0.6 ± 0.02
0.45 ± 0.04
30 ± 2.8
*43.3 ± 2.2
44 ± 1.5
48 ± 2.04
43.3 ± 3.1
*56.3 ± 2.9
45 ± 1.5
50 ± 1.9
Experimental design of cardiophysiological, pulmonary and systemic response
Telemetry (n = 7)
BALF (n = 6)
Lung tissue (n = 6)
Pulmonary histopathology (n = 2)
Blood A (n = 8)
Blood B (n = 8)
Heart tissue (n = 6)
Cardiac histopathology (n = 2)
Exposure to ambient air pollution has been associated with increased cardiovascular morbidity and mortality [1–4]. The currently emerging occupational and environmental burden of UFPs from the rapidly developing field of nanotechnology evokes concerns about the health effect of engineered nanoparticles (ultrafine) worldwide. Our exposure study specifically addresses the action of laboratory generated, airborne-like UFPs in the respiratory and the cardiovascular system as very little is known about the potential adverse effects and the underlying pathomechanisms. Findings from this work indicate increases in BP associated with striking activation of plasma rennin angiotensin system together with increases in circulating white blood cells and increased expressions for markers of pulmonary endothelial activation, blood coagulation, and oxidative stress in cardiovascular compromised UfCPs-exposed rats. Because these changes occur at UfCPs concentration which does not produce apparent pulmonary inflammation our results support epidemiological associations of elevated particle levels and cardiovascular impairment in individuals with preexisting diseases.
Compared to transient increases of HR and pulmonary neutrophilic inflammation during UfCPs exposure in WKY rats ; inhalation of UfCPs results in a prolonged increase in HR and BP in SHRs with a lag of 1–3 days, but no pulmonary neutrophilic inflammation. Lack of neutrophilic influx in association with no significant increase in MIP-2 and/TNF-α mRNA expression in SHRs suggests that the observed cardiovascular impairment is relatively independent of an apparent inflammatory response although an association to other observed pulmonary and systemic effects can not be ruled out. The lack of neutrophilic inflammation is very unusual as we have noted this happen in WKY rats similarly exposed to UfCPs . However; it is not totally surprising in SHRs as it has been shown in some studies that these rats (SHRs) require a greater insult to initiate inflammation than WKY . Although there is no neutrophilic inflammation in the lung but significant induction of HO-1, PAI-1, TF and other markers such as endothelin-1 is an indicator of pulmonary oxidative stress and injury. Considering this observation we hypothesize that SHRs (hypertensive individuals) are at higher risk and more susceptible or vulnerable to cardiovascular impairments following exposure to UFCPs compared to healthy WKY as no pulmonary injury or coagulative changes were observed in WKY similarly exposed to UfCPs .
A series of studies have shown that following exposure UFPs gain rapid access to pulmonary epithelial, interstitial and endothelial cells and can also be translocated from peripheral lungs to systemic circulation and extra-pulmonary organs in a considerable amount [17, 24, 25]. Therefore, it is probable that the detected cardiovascular impairments may primarily be due to the direct interaction of UfCPs with pulmonary tissue and at systemic level results in oxidative stress, activation of endothelial system, induction of blood coagulation factors, and inhibition of fibrinolysis together with induction of renin-angiotensin system at a systemic level.
UfCPs burden in the lungs and at systemic level
Responses to UfCPs were studied considering particle number and mass concentrations, which approximate peak ambient particulate matter burdens [26, 27]. Assuming a mean minute ventilation of 214 ml minutes-1  the rats in this study inhaled 308 liter of aerosol (172 μg m-3) in 24 h, resulting in an inhaled cumulative dose of approximately 53 μg UfCPs. It has been shown  that inhalation exposure of rat to ultrafine gold particle (mass median diameter: 49 nm) under similar conditions results in an alveolar deposition rate of 20%. Considering this deposition rate, the alveolar burden of UfCPs in our present experiment is ~10.6 μg or 5.5 × 1011 particles. With respect to our previous studies conducted in rats [17, 24] about 20% of the deposited dose, i.e. 2 μg/rat, is supposed to be rapidly translocated into pulmonary tissues and may exert direct intracellular effects in these tissues. According to the translocation studies  much less than 1 μg may be systemically available and less than 0.1 μg may reach the heart. These dose estimates corresponds to the dose that a healthy human will accumulate over one year when being exposed to common ambient levels of insoluble UFPs , i.e. 3 × 1011 UFPs will accumulate in the lungs and 6 × 108 UFPs in each of the secondary target organs (the estimate is based on a particle concentration of 1 × 103 cm-3, a daily inhaled gas volume of 1 × 104 l/d, and a deposition fraction in the peripheral lung of 0.3). However, ambient UFP concentration near busy roads may exceed the assumed particle number concentration substantially up to a factor of 100  and the deposition fraction may be higher in individuals suffering from respiratory diseases, e.g. ~70% in asthmatics . This suggest that the biological responses detected in the present study may be related to peak ambient ultrafine particle exposures to which humans may incidentally or accidentally be exposed to.
The cardiophysiological response in SHRs was characterized by a prolonged increase in BP and HR by about 5% during first to third day of the recovery period (p < 0.05). The extent of HR increase in UfCPs-exposed SHRs is consistent with other studies [33, 34] and that of our previous study  showing a significant elevation of HR by ~5% in WKY rats exposed to a comparable UfCPs concentration (180 μg m-3). However, in our previous study the normotensive (WKY) rats showed only increased HRs during the exposure period and did not exhibit any changes in BP. Similarly Gordent et al.  reported small but significant increases of HR (approximately 5%) in healthy rats during 6 h nose-only exposures to concentrated ambient particles (132 μg m-3-184 μg m-3). In SHRs about 8% increase of HR has been observed at much higher diesel particle concentrations [1000 μg m-3; . Furthermore, the mild but significant BP increase is comparable with the physiological endpoints from F-344 rats after exposure to urban ambient particles . Overall, BP and HR changes are admittedly small; however, with respect to the UfCPs exposure level selected, they are reasonable and likely to occur also in humans. Comparison of response patterns in healthy and compromised animals suggests that hypertensive animals are more susceptible to UfCPs particle exposure than normotensive. We detected a significant increase in BP and HR in SHRs over a period of 3 days after exposure to UfCPs. Whereas in other studies with uncompromised animal model, alteration of cardiovascular perfomance (HR and/or BP) was noted during the exposure and the values reach baseline levels rapidly after exposure [9, 33, 35].
Pulmonary and systemic inflammatory responses
A series of epidemiological studies have shown that exposure to ambient ultrafine particles is associated with pulmonary inflammation caused by deposition of particles in the alveoli [10, 37]. Particle exposure may results in local and systemic inflammatory responses [6, 11] and ultimately may lead to an activation of the coagulatory system [18, 19], increased plasma viscosity , vascular and endothelial dysfunction [14, 15]. Therefore, we assessed pulmonary and systemic inflammatory responses in order to shed light on pathophysiological pathways, which might be the plausible cause of UfCPs induced cardiovascular effects. No apparent inflammatory response has been detected in pulmonary tissue but a low grade inflammatory reaction cannot be ruled out. Plasma level of acute phase proteins such as HP and CRP were not affected by UfCPs exposure, but the observed small increases in the fraction of neutrophils and lymphocytes following 24 h exposure to UfCPs may indicate a small degree of systemic inflammation. Similar observations have been made by others and such phenomenon are suggested to contribute to the progression of atherosclerosis, hypertension and increased the risk of cardiopulmonary disease [38, 39]. The precise mechanism(s) of how systemic impairment is produced by inhalation of UfCPs and its consequence on cardiophysiology need to be explored.
Pulmonary and extra-pulmonary effects unrelated to inflammation
The pulmonary response of exposed SHRs is characterized by a significant induction of HO-1 (~2.5-fold), a sensitive marker for UfCPs mediated oxidative stress [40, 41], on the third day of recovery. The induced HO-1 is an indicator of a host defense mechanism for oxidative stress and is likely to be directly activated by UfCPs which have been shown to provide a substantial oxidative potency . The observed induction of PAI-1 (~2.5-fold) can be considered to be a downstream effect of particle induced oxidative stress . Increased levels of PAI-1, have been recognized as hallmarks of impaired endothelial function and are a common denominator of increased risk for cardiovascular disease . PAI-1 is known to be an inhibitor of fibrinolysis and regulator of vasoactivity , thus, increased levels of PAI-1 mRNA expression may also be involved in the observed increase in BP. Further, an increased TF expression (~2.5-fold) was detected in the lungs. Increased TF levels have been related to an increased risk of cardiac events because induction of TF is highly correlated with thrombogenesis and endothelial dysfunction [46, 47]. Activation of TF, the extrinsic coagulation pathway, in association with impaired fibrinolysis via PAI-1 activation suggests that UfCPs exposure induces endothelial dysfunction and activates the coagulatory pathway, both of which are correlated with overall cardiovascular risk [45–47].
Additionally, induction of ETA and ETB (~2.5-fold) along with a 6-fold induction of pulomonary ET-1 further supports the notion of an UfCPs induced endothelial dysfunction in the pulmonary circulation. The simultaneous increase in ETA and ET-1 indicates a synergistic effect because ET-1 contributes to endothelial dysfunction predominantly via ETA receptor stimulation . Potential health implications are obvious since several reports imply that both ETA and ETB are contributing to ET-1 induced hypertension [49, 50]. Moreover, up-regulation of ETB receptors is most notable in heart failure, hypertension and in artherosclesis formation .
Hence, the observed induction of the endothelin system (ET-1, ETA and ETB) and increased expression of coagulatory factors (PAI-1 and TF) in pulmonary tissue suggests that UfCPs exposure triggers important pathophysiological pathways in the lungs which have been associated with impaired cardiovascular performance and an increases risk for cardiovascular events.
Interestingly, in the heart of UfCPs exposed SHRs, the only marker being affected was the oxidative stress-inducible defense enzyme HO-1. Expression of HO-1 mRNA was more than 2-fold repressed in contrast to its up-regulation in the lung tissue. Our data do not allow to provide a final explanation for this observation, but under hypoxic conditions HO-1 mRNA is reported to be induced by a number of studies while others found a repression . It was suggested that the differential regulation and the different expression levels of HO-1 represent an adaptation or unrecognized defense strategy to stress and that the response can differ depending on cell and tissue type [52, 53]. Accordingly, we may value the different regulations observed for HO-1 in lung and cardiac tissue in the present study. However, we have to specify that we do not have any hint that UfCP exposure results in hypoxic conditions in cardiac tissue.
Systemic effects associated with cardiopulmonary impairments
The most interesting UfCPs-mediated systemic effect is the close association of increased BP in exposed SHRs (Figure 2a) with a significant increase of circulating PRC at the same time points (Figure 5a). The tendency of increased Ang I and II concentrations on the first day of recovery further supports the notion that the RAS is primarily involved in the UfCPs-mediated BP increase detected in exposed SHRs [54–56]. On the other hand, the enzymatic activity of renin appears not to be affected by UfCPs exposure. Renin is a rate-limiting enzyme determining the overall RAS activity. It converts plasma angiotensinogen to Ang I, which is subsequently converted to Ang II, one of the most powerful vasoconstrictor. The RAS system is typically associated with the perfusion of the kidney, however, several recent studies reported that local RAS exist which is physiologically active in different tissues like lung, heart, kidney, or brain [55, 57, 58]. Besides regulating regional perfusion, local RAS may also play an important role in regulating systemic blood pressure [55, 57, 58]. Therefore, induced RAS in plasma might be due to direct effect of UfCPs in the pulmonary tissue, resulting in local RAS activation and systemic blood pressure elevation.
We have shown that inhalation of UfCPs at concentrations reflecting peak ambient exposures results in a moderate (about 5%) increase in HR and BP in SHRs with a lag of 1–3 days which is paralleled by the induction of renin-angiotensin system in plasma, potentially being due to an activation of the local pulmonary rennin-angiotensin system. Specifically in pulmonary tissue markers of oxidative stress (HO-1), the endothelin system (ETA, ETB and ET-1) and the coagulation system (PAI-1 and TF) were found to be activated by UfCPs exposure. Since various inflammatory markers in pulmonary tissues (TNF-α, MIP-2; IL-6) were not affected and neutrophil cell recruitment was not observed, the UfCPs induced effects appear to be unrelated to a traceable pulmonary inflammation. At the systemic level different inflammatory markers (acute phase protein: CRP, HP) were also not affected, but the observed increases in neutrophils and lymphocytes following 24 h exposure to UfCPs suggest a possible low degree of systemic inflammation. Therefore, our findings imply that UfCPs exposure at levels below detectable pulmonary inflammation triggers distinct effects in pulmonary tissues and at systemic levels that can promote further cardiovascular impairment in SHRs. Since dose estimates revealed that the burden of UfCP delivered to the rats exceeds that caused by common urban levels in humans the observed biological effects may only be related to peak ambient ultrafine particle exposures, e.g. at busy rods, to which humans are incidentally or accidentally be exposed to. Based on the response detected in SHRs – as a model for impaired cardiovascular individuals – as well as those observed in healthy WKY rats  we reciprocate the epidemiological findings that predisposed individuals are at higher risk and more susceptible to cardiovascular impairments following exposure to UfCPs than healthy ones.
Male spontaneously hypertensive rats (SHR; 6 month) were used for the present study. Animals were housed under filtered air and specific pathogen free (SPF) conditions at a mean temperature of 22 ± 2°C, a mean relative humidity of 50 ± 5%, and a 12 h light-dark cycle (6 a.m. to 6 p.m. light on) with pelleted feed and filtered water being supplied ad libitum. Experimental protocols were approved by the Animal Care and Use Committee of the HelmholtzZentrum München – German Research Center for Environmental Health and by the Bavarian Animal Research Authority (211-2531-88/2001).
Ultrafine carbon particle generation and whole body exposure chamber
The methodology of UfCPs generation and the setup of the whole body exposure system for rodent have been previously described [9, 59]. UfCPs showed a monomodal number distribution in the exposure chamber with a median particle size ± arithmetic SD of 31 ± 0.3 nm. Measured mass and number concentration was 172 μg m-3 and 9× 106cm-3, respectively. This translates into a surface area concentration of 0.139 m2(particle) m-3 (air) because the mass specific surface area (according to the BET method) of the UfCPs was determined to be 807 m2 g-1. Based on the polydispersity of the particle distribution (geometric standard deviation is 1.51) a median mass diameter of 46 nm is calculated.
Table 2 provides an overview of the experimental design. Primarily, the cardiophysiological responses, i.e. effects on HR and BP were measured in 7 SHRs following 24 h UfCPs inhalation exposure using a radio telemetry system. Since BP and HR were increased on first to third day of recovery, the subsequent exposures were conducted in additional, non-telemetry SHRs to obtain blood, BALF and tissue samples from the first and third day of recovery. Each exposure used 16 SHRs, 8 animals were exposed to filtered air (controls) while the other 8 animals were exposed to UfCPs for 24 h (exposed). In the first study, animals were sacrificed in the morning of the first day of recovery. Prior to BALF collection, blood samples (blood A) of 8 SHRs were collected from retro orbital sinus for analysis of haematological parameters and from the abdominal aorta for analysis of biomarkers. Six animals were used to collect BALF and tissue samples (heart and lung) for further assessment of pulmonary and systemic response, the remaining 2 SHRs of each group were used for pulmonary and cardiac histopathology. Animal distribution and sample collection of the control group was similar to that of the exposed group.
In the second inhalation study, SHRs were sacrificed in the morning on third day of recovery. Blood sampling from retro orbital sinus and abdominal aorta (blood A), BALF and tissue samples collection, as well as cardiac histopathology were carried out as described above. In addition, 400 μl of blood from the caudal vein of each animal (blood B) was collected in the morning before exposure (base line) and on the first, second and third day of recovery to assess plasma renin concentration and activity.
Cardiophysiological analysis by radiotelemetry
Cardiophysiological response prior to and following inhalation exposure to UfCPs was performed on 7, 6 months old SHRs (360 ± 11 g) by using radio telemetric system as described in our previous study  (Dataquest A.R.T; Data Sciences International D.S.I., St. Paul MN, U.S.A). The implantation of telemetric devices into the peritoneal cavity of animals was performed as previously described . All animals exhibited rapid post surgical recovery, with resumption of normal food and water intake within 24 h of surgery. They returned to presurgical body weight (excluding the weight of the implant) on average within 3–4 days and did not exhibit any signs of post surgical complications. After 10 days of post surgical recovery, the animals were acclimatized in the exposure chamber for two days (day -2 and day -1). We have observed that following 2 days of acclimatization in the exposure chamber prior to the actual data recording cardiovascular response (BP and HR) reaches to its baseline values. Data recording was then initiated and continued for six days (Figure 1), that included a baseline reading (day 0), exposure (day 1), and recovery period readings (days 2–5).
In this study the individual animals served as their own controls. Applying the above defined exposure protocol animals were primarily exposed to filtered air (control) and 4 weeks later to UfCPs by whole-body exposure. A time gap of 4 weeks was chosen to ensure elimination of any possible effects of clean air exposure. Comparison of baseline values between 6 and 7 months old SHRs indicate that cardiac performance was not altered by the 4 week time gap between control and exposure conditions (see baseline values in results). Moreover, no significant changes of cardiovascular performance (mBP and HR; Figures 2a and 2b) was noted in SHRs following exposure to filtered air.
Animal preparation, data acquisition and analysis using radio telemetry system
The implantation of telemetric devices into the peritoneal cavity of animals (n = 7), the radio telemetric data acquisition and analysis were performed as described previously .
Briefly, arterial BP, HR, body core temperature (T), and physical activity (Act) of SHRs were continuously collected over 24 h/day, throughout baseline, exposure and recovery periods. Systolic (sBP), diastolic (dBP), and mean (mBP) arterial blood pressure were determined from the BP tracings on a beat to beat basis. The data of each animal were then processed to obtain 10-minutes average segments per rat for each of the measured parameters (Figure 1). For the final data analysis, we only have considered the values of each parameter from the 12 h dark period (6 p.m. to 6 a.m.), as animals are more active during the night time. Thereby, 72 consecutive values of 10-minutes data segments were obtained per rat per day and per parameter. Since we did not observe a time dependency of particle associated effects during the 12 h period in each of the exposed animals, mean values were used for further data processing. For all of the measured parameters, we averaged the 72 values obtained for each day resulting in one mean value per parameter per rat and per day. Based on these values, group mean averages were calculated on a daily bases for the whole study and were used for statistical comparison between filtered air (control) and UfCPs exposed SHRs.
For heart-rate variability (HRV) analysis, a different procedure has to be applied . For the 12 h dark periods, one 5-minutes ECG segment per hour was randomly selected and used for further HRV analysis. For each of these 5-minutes segments the standard deviation of all adjacent normal sinus NN intervals (SDNN) was determined as a measure of the overall HRV. In addition, the square root of the mean of squared differences between adjacent normal to normal intervals (RMSSD) and the low-frequency to high-frequency ratio (LF/HF), reflecting the balance of cardiac parasympathetic tone and sympathetic activity, respectively, were determined. Further data processing to obtain daily averages for each of the rats and group averages followed the procedure described above for the other parameters.
Assessment of UfCPs-mediated pulmonary inflammatory response
BALF and lung
BALF analysis was performed as described in our previous study . In brief, one aliquot of whole BALF (n = 6) was used for determining total cell counts (Coulter Counter; Coulter, Inc., Miami, FL), and a second aliquot was centrifuged (Cytospin 2; Shandon, Astmoor, UK) to counts cell differential. Macrophages, polymorphonuclear cells (PMNs, or neutrophil), eosinophil, and lymphocyte were counted using light microscopy (over 200 cells counted per slide). The remaining BALF was centrifuged (1500 × g) to remove cells, and the supernatant fluids were analyzed for protein, albumin concentration and γ-Glutamyltransferase (GGT), N-acetyl glucosaminidase (NAG) activity as potential biological markers for pulmonary capillary leakage and lung injury . Furthermore, transcript profiling markers associated with pulmonary inflammation (MIP-2, TNF-α), were assessed from the lung tissues (n = 6) using real-time RT-PCR (see gene expression analysis).
The left lung of each non lavaged animal (n = 2) was infused via left main bronchus by 4% buffered formalin at 20 cm water pressure for 20–30 minutes. The main bronchus was then tied and the lung was submerged in fixative until processing for histology. Paraffin blocks were prepared from dehydrated tissues and 3- to 4-μm sections were stained with hematoxylin and eosin for light microscopic evaluation of the pulmonary tissues .
Assessment of UfCPs-mediated effects on pulmonary and cardiac tissue
Gene expression analysis
For gene expression analysis lung and heart tissues were collected from each animals (n = 6) immediately after BALF collection, placed in vials and flash frozen in liquid nitrogen. They were then stored at -80°C until extraction of RNA.
Total RNA was extracted from these tissue samples using the RNeasy (lung) or RNeasy fibrous tissue (heart) kits and protocols obtained from Qiagen. RNasin Plus (Promega), a broad spectrum RNase inhibitor, was added to each sample immediately after isolation from the tissue. Concentration and purity of the RNA samples were determined with the NanoDrop ND-100 spectrophotometer (NanoDrop Technologies). Aliquots of each sample were diluted to a concentration suitable for PCR and the stock samples and dilutions were stored at -80°C.
Gene expression assays
Target sequences of the labelled probes used for detection of genes following amplification of cDNA using real time PCR
Target Probe Sequence**
Hypoxanthine guanine phosphoribosyl transferase (HPRT)
Serine (or cysteine) peptidase inhibitor, claude E, member1 (PAI; plasminogen activator inhibitor-1)
Coagulation Factor 3 (TF; Tissue Factor)
Heme Oxygenase-1 (HO-1)
Chemokine (C-X-C motif) ligand 2 (MIP-2; macrophage inflammatory protein-2; MIP-2)
Tumor Necrosis Factor alpha (TNF-α)
Endothelin 1 (ET-1)
Endothelin Receptor A (ETA)
Endothelin Receptor B (ETB)
The whole heart of each non lavaged animal (n = 2) was submerged in fixative until processing for histology. Paraffin blocks were prepared from dehydrated tissues and 3- to 4-μm sections were stained with hematoxylin and eosin for light microscopic evaluation of the cardiac histopathology .
Assessment of UfCPs-mediated systemic response
Haematological analysis, measurement of different biomarkers from plasma and serum were used for the assessment of systemic response following UfCPs exposure. Blood samples (blood A, Table 2) of each animal were collected from retro orbital sinus (haematology) and from abdominal aorta (biomarkers) on first and third day of recovery. For analysis of plasma renin concentration and activity, blood samples (blood B, Table 2) were also collected from caudal vein at several time points.
For haematological analysis, 500 μl of blood sample from retro orbital sinus of each animal (blood A, n = 8) was collected in EDTA-Microvette and analysed by using haematology analyzer (Bayer ADVIA 120, Germany).
Acute phase proteins analysis
Blood samples collected from each animals (blood A, n = 8) were stored in aliquots of 2.6 ml in 2.9 ml S-Monovette® tube (Sarstedt, Germany) with or without anticoagulant (citrate and EDTA) for further analysis of different markers. Each blood sample with anticoagulant was centrifuged (at 2710 g) for 10-minutes (4°C) for the collection of plasma sample and stored at -80°C until analysed. Fibrinogen concentration was measured from each plasma samples as previously described . C-reactive protein (CRP) and haptoglobin (HP) were analysed from serum collected from blood samples by centrifugation for 15-minutes (at 1300 g, 4°C). CRP and HP were measured by using kit from DiaSorin Inc. (Stillwater, MN) for controls and standards, except the standard for CRP, which was obtained from Kamiya Biomedical Company (Seattle, WA).
Related to the limited amount of blood which can be taken repeatedly from a rat, blood samples collected from caudal vein (blood B, n = 8) before exposure, on the first, second, and third day of recovery were used to analyse only plasma renin concentration and activity. In this case 400 μl of blood samples from each animal were collected from the caudal vein in a 2 ml Eppendorf cup containing 25 μl mixture of 2.5 ml EDTA (Merck, Germany) and 25 μl of Phenantrolin (Calbiochem, Germany).
Furthermore concentration of angiotensin I (Ang I) and angiotensin II (Ang II) were determined from plasma on first and third recovery day. For this purpose blood samples were collected from abdominal aorta (blood A, n = 8) in a 5 ml falcon tube containing mixture (140 μl/ml blood) of p-hydroxy-mercuribenzoic acid (10 μl, Sigma), phenyl-methyl-sulfonyl-fluoride (10 μl, Sigma), EDTA (50 μl), pepstatin A (20 μl, Sigma) and o-phenanathrolin (50 μl, Merck). Measurements of renin activity and concentration as well as angiotensin (I and II) concentrations were assayed employing specific radioimmunoassays, as previously described .
After checking for the normal distribution assumption the differences between exposure and control groups were compared by using the t-test. Cardiovascular response parameters were described by a linear mixed regression model for repeated measurements. Based on this model group differences between the exposure and control group were tested. For expression analysis of various parameters from lung and heart tissues, a two-way analysis of variance (ANOVA) was used to analyze differences between the groups. However, for the plasma rennin and angiotensin (I and II) data the normailtiy assumption does not hold. Therefore, for plasma rennin and angiotensin (I and II) concentration the Wilcoxon rank sum test was performed. P values less than 0.05 were stated as statistically significant. All computations were done by the software packages Statgraphics plus v5.0 (Manugistics, Rockville, MD) and SAS V9.1 (Cary, NC). Data are presented as arithmetic mean values of n observations ± the standard error (SE), unless otherwise indicated.
- Ang I &II:
Angiotensin I & II
Arterial blood pressure
Heart rate variability
Low frequency (0.20 Hz to 0.75 Hz) to high frequency (0.75 Hz to 2.5 Hz) ratio
Macrophage inflammatory protein-2
ultrafine carbon particles
Plasminogen activator inhibitor-1
Plasma renin concentarton
Square root of the mean of squared differences between adjacent NN (normal-to-normal) intervals
Standard deviation of all normal sinus NN (normal-to-normal) intervals
Spontaneously hypertensive rats
Body core temperature
Tumor necrosis factor-alpha.
The authors would like to thank Bärbel Ritter and Maria Neuner for their excellent technical assistance.
- Hoffmann B, Moebus S, Möhlenkamp S, Stang A, Lehmann N, Dragano N, Schmermund A, Memmesheimer M, Mann K, Erbel R, Jöckel KH: Residential exposure to traffic is associated with coronary atherosclerosis. Circulation 2007, 116(Suppl 5):489–496. 10.1161/CIRCULATIONAHA.107.693622View ArticlePubMedGoogle Scholar
- Pope CA 3rd, Hansen ML, Long RW, Nielsen KR, Eatough NL, Wilson WE, Eatough DJ: Ambient particulate air pollution, heart rate variability, and blood markers of inflammation in a panel of elderly subjects. Environ Health Perspect 2004, 112(Suppl 3):339–345.PubMed CentralPubMedGoogle Scholar
- Pope CA 3rd, Muhlestein JB, May HT, Renlund DG, Anderson JL, Horne BD: Ischemic heart disease events triggered by short-term exposure to fine particulate air pollution. Circulation 2006, 114(Suppl 23):2443–2448. 10.1161/CIRCULATIONAHA.106.636977View ArticlePubMedGoogle Scholar
- Timonen KL, Vanninen E, de Hartog J, Ibald-Mulli A, Brunekreef B, Gold DR, Heinrich J, Hoek G, Lanki T, Peters A, Tarkiainen T, Tiittanen P, Kreyling W, Pekkanen J: Effects of ultrafine and fine particulate and gaseous air pollution on cardiac autonomic control in subjects with coronary artery disease: the ULTRA study. J Expo Sci Environ Epidemiol 2006, 16(Suppl 4):332–341. 10.1038/sj.jea.7500460View ArticlePubMedGoogle Scholar
- Cozzi E, Wingard CJ, Cascio WE, Devlin RB, Miles JJ, Bofferding AR, Lust RM, Van Scott MR, Henriksen RA: Effect of ambient particulate matter exposure on hemostasis. Transl Res 2007, 149(Suppl 6):324–32. 10.1016/j.trsl.2006.12.009View ArticlePubMedGoogle Scholar
- Schulz H, Harder V, Ibald-Mulli A, Khandoga A, Koenig W, Krombach F, Radykewicz R, Stampfl A, Thorand B, Peters A: Cardiovascular effects of fine and ultrafine particles. J Aerosol Med 2005, 18(Suppl 1):1–22. 10.1089/jam.2005.18.1View ArticlePubMedGoogle Scholar
- Cyrys J, Stölzel M, Heinrich J, Kreyling WG, Menzel N, Wittmaack K, Tuch T, Wichmann HE: Elemental composition and sources of fine and ultrafine ambient particles in Erfurt, Germany. Sci Total Environ 2003, 305(Suppl 1–3):143–156. 10.1016/S0048-9697(02)00494-1View ArticlePubMedGoogle Scholar
- Chen LC, Hwang JS: Characterization of acute and chronic effects of ambient air fine particulate matter exposures on heart-rate variability. Inhal Toxicol 2005, 17(Suppl 4–5):209–216. 10.1080/08958370590912789View ArticlePubMedGoogle Scholar
- Harder V, Gilmour P, Lentner B, Karg E, Takenaka S, Ziesenis A, Stampfl A, Kodavanti U, Heyder J, Schulz H: Cardiovascular responses in unrestrained WKY rats to inhaled ultrafine carbon particles. Inhal Toxicol 2005, 17(Suppl 1):29–42. 10.1080/08958370590885681View ArticlePubMedGoogle Scholar
- Pope CA 3rd, Burnett RT, Thurston GD, Thun MJ, Calle EE, Krewski D, Godleski JJ: Cardiovascular mortality and long-term exposure to particulate air pollution: epidemiological evidence of general pathophysiological pathways of disease. Circulation 2004, 109(1):71–77. 10.1161/01.CIR.0000108927.80044.7FView ArticlePubMedGoogle Scholar
- Donaldson K, Tran L, Jimenez LA, Duffin R, Newby DE, Mills N, MacNee W, Stone V: Combustion-derived nanoparticles: a review of their toxicology following inhalation exposure. Part Fibre Toxicol 2005., 2(10):
- Peters A, Döring A, Wichmann HE, Koenig W: Increased plasma viscosity during an air pollution episode: a link to mortality? Lancet 1997, 349(Suppl 9065):1582–1587. 10.1016/S0140-6736(97)01211-7View ArticlePubMedGoogle Scholar
- Seaton A, MacNee W, Donaldson K, Godden D: Particulate air pollution and acute health effects. Lancet 1995, 345(Suppl 8943):176–178. 10.1016/S0140-6736(95)90173-6View ArticlePubMedGoogle Scholar
- Mills NL, Törnqvist H, Robinson SD, Gonzalez M, Darnley K, MacNee W, Boon NA, Donaldson K, Blomberg A, Sandstrom T, Newby DE: Diesel exhaust inhalation causes vascular dysfunction and impaired endogenous fibrinolysis. Circulation 2005, 112(Suppl 25):3930–3936. 10.1161/CIRCULATIONAHA.105.588962View ArticlePubMedGoogle Scholar
- Törnqvist H, Mills NL, Gonzalez M, Miller MR, Robinson SD, Megson IL, Macnee W, Donaldson K, Söderberg S, Newby DE, Sandström T, Blomberg A: Persistent endothelial dysfunction in humans after diesel exhaust inhalation. Am J Respir Crit Care Med 2007, 176(Suppl 4):395–400. 10.1164/rccm.200606-872OCView ArticlePubMedGoogle Scholar
- Oberdörster G, Sharp Z, Atudorei V, Elder A, Gelein R, Kreyling W, Cox C: Translocation of inhaled ultrafine particles to the brain. Inhal Toxicol 2004, 16(Suppl 6–7):437–445. 10.1080/08958370490439597View ArticlePubMedGoogle Scholar
- Semmler M, Seitz J, Erbe F, Mayer P, Heyder J, Oberdörster G, Kreyling WG: Long-term clearance kinetics of inhaled ultrafine insoluble iridium particles from the rat lung, including transient translocation into secondary organs. Inhal Toxicol 2004, 16(Suppl 6–7):453–459. 10.1080/08958370490439650View ArticlePubMedGoogle Scholar
- Khandoga A, Stampfl A, Takenaka S, Schulz H, Radykewicz R, Kreyling W, Krombach F: Ultrafine particles exert prothrombotic but not inflammatory effects on the hepatic microcirculation in healthy mice in vivo. Circulation 2004, 109(Suppl 10):1320–1325. 10.1161/01.CIR.0000118524.62298.E8View ArticlePubMedGoogle Scholar
- Nemmar A, Nemery B, Hoet PH, Van Rooijen N, Hoylaerts MF: Silica particles enhance peripheral thrombosis: key role of lung macrophage-neutrophil cross-talk. Am J Respir Crit Care Med 2005, 171(Suppl 8):872–879. 10.1164/rccm.200409-1202OCView ArticlePubMedGoogle Scholar
- Cozzi E, Hazarika S, Stallings HW 3rd, Cascio WE, Devlin RB, Lust RM, Wingard CJ, Van Scott MR: Ultrafine particulate matter exposure augments ischemia-reperfusion injury in mice. Am J Physiol Heart Circ Physiol 2006, 291(Suppl 2):H894–903. 10.1152/ajpheart.01362.2005View ArticlePubMedGoogle Scholar
- Peters A, Veronesi B, Calderón-Garcidueñas L, Gehr P, Chen LC, Geiser M, Reed W, Rothen-Rutishauser B, Schürch S, Schulz H: Translocation and potential neurological effects of fine and ultrafine particles a critical update. Part Fibre Toxicol 2006, 3: 1–13. 10.1186/1743-8977-3-13View ArticleGoogle Scholar
- Hermann K, Ganten D, Unger T, Bayer C, Lang RE: Measurement and characterization of angiotensin peptides in plasma. Clin Chem 1988, 34(6):1046–1051.PubMedGoogle Scholar
- Kodavanti UP, Schladweiler MC, Ledbetter AD, McGee JK, Walsh L, Gilmour PS, Highfill JW, Pinkerton KE, Richards JH, Crissman K, Andrews D, Costa DL: Consistent pulmonary and systemic responses from inhalation of fine concentrated ambient particles: Roles of rat strains used and physicochemical properties. Environ Health Perspect 2005, 113: 1561–1568.PubMed CentralView ArticlePubMedGoogle Scholar
- Geiser M, Rothen-Rutishauser B, Kapp N, Schürch S, Kreyling W, Schulz H, Semmler M, Im Hof V, Heyder J, Gehr P: Ultrafine particles cross cellular membranes by nonphagocytic mechanisms in lungs and in cultured cells. Environ Health Perspect 2005, 113(11):1555–1560.PubMed CentralView ArticlePubMedGoogle Scholar
- Kreyling WG, Semmler M, Erbe F, Mayer P, Takenaka S, Schulz H, Oberdörster G, Ziesenis A: Translocation of ultrafine insoluble iridium particles from lung epithelium to extrapulmonary organs is size dependent but very low. J Toxicol Environ Health A 2002, 65(Suppl 20):1513–1530. 10.1080/00984100290071649View ArticlePubMedGoogle Scholar
- Chaloulakou A, Kassomenos P, Spyrellis N, Demokritou P, Koutrakis P: Measurements of PM10and PM2.5particle concentrations in Athens, Greece. Atmospheric Environment 2003, 37(Suppl 5):649–660. 10.1016/S1352-2310(02)00898-1View ArticleGoogle Scholar
- Tuch TH, Brand P, Wichmann HE, Heyder J: Variation of particle number and mass concentration in various size ranges of ambient aerosols in Eastern Germany. Atmospheric Environment 1997, 31(Suppl 24):4193–4197. 10.1016/S1352-2310(97)00260-4View ArticleGoogle Scholar
- Schmid O, Bolle I, Harder V, Karg E, Takenaka S, Schulz H, Ferron GA: Model for the deposition of aerosol particles in the respiratory tract of the rat. I. Nonhygroscopic particle deposition. J Aerosol Med Pulm Drug Deliv 2008, 21(Suppl 3):291–308. 10.1089/jamp.2008.0689View ArticlePubMedGoogle Scholar
- Takenaka S, Karg E, Kreyling WG, Lentner B, Möller W, Behnke-Semmler M, Jennen L, Walch A, Michalke B, Schramel P, Heyder J, Schulz H: Distribution pattern of inhaled ultrafine gold particles in the rat lung. Inhal Toxicol 2006, 18(Suppl 10):733–740. 10.1080/08958370600748281View ArticlePubMedGoogle Scholar
- Kreyling WG, Möller W, Semmler-Behnke M, Obersdörster G: Particle Dosimetry: Deposition and clearance from the Respiratory Tract and Translocation Towards Extra-Pulmonary Sites. In Particle Toxicology. Edited by: Donaldson K, Borm P. New York: CRC Press/Taylor & Francis; 2007:48–69.Google Scholar
- Kittelson DB, Watts WF, Johnson JP: Nanoparticle emissions on Minnesota highways. Atmospheric Environment 2004, 38: 9–19. 10.1016/j.atmosenv.2003.09.037View ArticleGoogle Scholar
- Chalupa DC, Morrow PE, Oberdörster G, Utell MJ, Frampton MW: Ultrafine particle deposition in subjects with asthma. Environ Health Perspect 2004, 112(8):879–882.PubMed CentralView ArticlePubMedGoogle Scholar
- Campen MJ, McDonald JD, Gigliotti AP, Seilkop SK, Reed MD, Benson JM: Cardiovascular effects of inhaled diesel exhaust in spontaneously hypertensive rats. Cardiovasc Toxicol 2003, 3(Suppl 4):353–361. 10.1385/CT:3:4:353View ArticlePubMedGoogle Scholar
- Gordon T, Nadziejko C, Schlesinger R, Chen LC: Pulmonary and cardiovascular effects of acute exposure to concentrated ambient particulate matter in rats. Toxicol Lett 1998, 96–97: 285–288. 10.1016/S0378-4274(98)00084-8View ArticlePubMedGoogle Scholar
- Gordon T, Nadziejko C, Chen LC, Schlesinger R: Effects of concentrated ambient particles in rats and hamsters: an exploratory study. Res Rep Health Eff Inst 2000, (93):5–34.Google Scholar
- Vincent R, Kumarathasan P, Goegan P, Bjarnason SG, Guénette J, Bérubé D, Adamson IY, Desjardins S, Burnett RT, Miller FJ, Battistini B: Inhalation toxicology of urban ambient particulate matter: Acute cardiovascular effects in rats. Res Rep Health Effects Inst 2001, (104):5–54.Google Scholar
- Peters A, Schneider A, Greven S, Bellander T, Forastiere F, Ibald-Mulli A, Illig T, Jacquemin B, Katsouyanni K, Koenig W, Lanki T, Pekkanen J, Pershagen G, Picciotto S, Rückerl R, Rosario AS, Stefanadis C, Sunyer J: Air pollution and inflammatory response in myocardial infarction survivors: gene-environment interactions in a high-risk group. Inhal Toxicol 2007, 19(Suppl 1):161–175. 10.1080/08958370701496129View ArticlePubMedGoogle Scholar
- Ofosu-Appiah W, Sfeir G, Smith D, Richard T: Neutrophil-mediated damage to vascular endothelium in the spontaneously hypertensive rat. Clin Immunol Immunopathol 1997, 83(Suppl 3):293–301. 10.1006/clin.1997.4361View ArticlePubMedGoogle Scholar
- Suwa T, Hogg JC, Quinlan KB, Ohgami A, Vincent R, van Eeden SF: Particulate air pollution induces progression of atherosclerosis. J Am Coll Cardiol 2002, 39(Suppl 6):935–942. 10.1016/S0735-1097(02)01715-1View ArticlePubMedGoogle Scholar
- Koike E, Kobayashi T: Chemical and biological oxidative effects of carbon black nanoparticles. Chemosphere 2006, 65(Suppl 6):946–951. 10.1016/j.chemosphere.2006.03.078View ArticlePubMedGoogle Scholar
- Xia T, Kovochich M, Brant J, Hotze M, Sempf J, Oberley T, Sioutas C, Yeh JI, Wiesner MR, Nel AE: Comparison of the abilities of ambient and manufactured nanoparticles to induce cellular toxicity according to an oxidative stress paradigm. Nano Lett 2006, 6(Suppl 8):1794–1807. 10.1021/nl061025kView ArticlePubMedGoogle Scholar
- Stoeger T, Takenaka S, Frankenberger B, Ritter B, Karg E, Maier K, Schulz H, Schmid O: Deducing In Vivo Toxicity of Combustion-Derived Nanoparticles from a Cell-Free Oxidative Potency Assay and Metabolic Activation of Organic Compounds. Environ Health Persp 2008.Google Scholar
- Dimova EY, Samoylenko A, Kietzmann T: Oxidative stress and hypoxia: implications for plasminogen activator inhibitor-1 expression. Antioxid Redox Signa 2004, 6(Suppl 4):777–791. 10.1089/1523086041361596View ArticleGoogle Scholar
- Brodsky SV, Malinowski K, Golightly M, Jesty J, Goligorsky MS: Plasminogen activator inhibitor-1 promotes formation of endothelial microparticles with procoagulant potential. Circulation 2002, 106(Suppl 18):2372–2378. 10.1161/01.CIR.0000033972.90653.AFView ArticlePubMedGoogle Scholar
- Poli KA, Tofler GH, Larson MG, Evans JC, Sutherland PA, Lipinska I, Mittleman MA, Muller JE, D'Agostino RB, Wilson PW, Levy D: Association of blood pressure with fibrinolytic potential in the Framingham offspring population. Circulation 2000, 101(3):264–269.View ArticlePubMedGoogle Scholar
- Gilmour PS, Nyska A, Schladweiler MC, McGee JK, Wallenborn JG, Richards JH, Kodavanti UP: Cardiovascular and blood coagulative effects of pulmonary zinc exposure. J Toxicol Appl Pharmacol 2006, 211(Suppl 1):41–52. 10.1016/j.taap.2005.06.002View ArticleGoogle Scholar
- Karoly ED, Li Z, Dailey LA, Hyseni X, Huang YC: Up-regulation of tissue factor in human pulmonary artery endothelial cells after ultrafine particle exposure. Environ Health Perspect 2007, 115(4):535–540.PubMed CentralView ArticlePubMedGoogle Scholar
- Halcox JP, Nour KR, Zalos G, Quyyumi AA: Endogenous endothelin in human coronary vascular function: differential contribution of endothelin receptor types A and B. Hypertension 2007, 49(Suppl 5):1134–1141. 10.1161/HYPERTENSIONAHA.106.083303View ArticlePubMedGoogle Scholar
- Sauvageau S, Thorin E, Caron A, Dupuis J: Endothelin-1-induced pulmonary vasoreactivity is regulated by ET(A) and ET(B) receptor interactions. J Vasc Res 2007, 44(Suppl 5):375–381. 10.1159/000102534View ArticlePubMedGoogle Scholar
- Seo B, Oemar BS, Siebenmann R, von Segesser L, Lüscher TF: Both ETA and ETB receptors mediate contraction to endothelin-1 in human blood vessels. Circulation 1994, 89(3):1203–1208.View ArticlePubMedGoogle Scholar
- Schneider MP, Boesen EI, Pollock DM: Contrasting actions of endothelin ET(A) and ET(B) receptors in cardiovascular disease. Annu Rev Pharmacol Toxicol 2007, 47: 731–759. 10.1146/annurev.pharmtox.47.120505.105134PubMed CentralView ArticlePubMedGoogle Scholar
- Nakayama M, Takahashi K, Kitamuro T, Yasumoto K, Katayose D, Shirato K, Fujii-Kuriyama Y, Shibahara S: Repression of heme oxygenase-1 by hypoxia in vascular endothelial cells. Biochem Biophys Res Commun 2000, 271(Suppl 3):665–671. 10.1006/bbrc.2000.2683View ArticlePubMedGoogle Scholar
- Srisook K, Kim C, Cha YN: Molecular mechanisms involved in enhancing HO-1 expression: de-repression by heme and activation by Nrf2, the "one-two" punch. Antioxid Redox Signal 2005, 7(Suppl 11–12):1674–1687. 10.1089/ars.2005.7.1674View ArticlePubMedGoogle Scholar
- Bader M: Role of the local renin-angiotensin system in cardiac damage: a minireview focussing on transgenic animal models. J Mol Cell Cardiol 2002, 34(Suppl 11):1455–1462. 10.1006/jmcc.2002.2077View ArticlePubMedGoogle Scholar
- Lavoie JL, Sigmund CD: Minireview: overview of the renin-angiotensin system-an endocrine and paracrine system. Endocrinology 2003, 144(Suppl 6):2179–2183. 10.1210/en.2003-0150View ArticlePubMedGoogle Scholar
- Sachetelli S, Liu Q, Zhang SL, Liu F, Hsieh TJ, Brezniceanu ML, Guo DF, Filep JG, Ingelfinger JR, Sigmund CD, Hamet P, Chan JS: RAS blockade decreases blood pressure and proteinuria in transgenic mice overexpressing rat angiotensinogen gene in the kidney. Kidney Int 2006, 69(Suppl 6):1016–1023. 10.1038/sj.ki.5000210View ArticlePubMedGoogle Scholar
- Kuba K, Imai Y, Penninger JM: Angiotensin-converting enzyme 2 in lung diseases. Curr Opin Pharmacol 2006, 6(Suppl 3):271–276. 10.1016/j.coph.2006.03.001View ArticlePubMedGoogle Scholar
- Paul M, Poyan Mehr A, Kreutz R: Physiology of local renin-angiotensin systems. Physiol Rev 2006, 86(Suppl 3):747–803. 10.1152/physrev.00036.2005View ArticlePubMedGoogle Scholar
- Karg E, Roth C, Heyder J: Do inhaled ultrafine particles cause acute health effects in rats? II: Exposure system. J Aerosol Sci 1998, 29(Suppl 1):315–316. 10.1016/S0021-8502(98)00465-0View ArticleGoogle Scholar
- Kodavanti UP, Schladweiler MC, Ledbetter AD, Hauser R, Christiani DC, McGee J, Richards JR, Costa DL: Temporal association between pulmonary and systemic effects of particulate matter in healthy and cardiovascular compromised rats. J Toxicol Environ Health A 2002, 65(Suppl 20):1545–1569. 10.1080/00984100290071667View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.